Pulmonary Hypertension in COPD

References

1. 1.↵
   1. Barberà JA,
   2. Blanco I

   . Pulmonary hypertension in patients with chronic obstructive pulmonary disease, advances in pathophysiology and management. Drugs 2009;69(9):1153-1171.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Thabut G,
   2. Dauriat G,
   3. Stern JB,
   4. Logeart D,
   5. Lévy A,
   6. Marrash-Chahla R,
   7. Mal H

   . Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005;127(5):1531-1536.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Chaouat A,
   2. Naeije R,
   3. Weitzenblum E

   . Pulmonary hypertension in COPD. Eur Respir J 2008;32(5):1371-1385.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Chaouat A,
   2. Bugnet AS,
   3. Kadaoui N,
   4. Schott R,
   5. Enache I,
   6. Ducoloné A,
   7. et al

   . Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172(2):189-194.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Oswald-Mammoser M,
   2. Weitzenblum E,
   3. Quoix E,
   4. Moser G,
   5. Chaouat A,
   6. Charpentier C,
   7. Kessler R

   . Prognostic factors in COPD patients receiving long-term oxygen therapy: importance of pulmonary artery pressure. Chest 1995;107(5):1193-1198.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Scharf SM,
   2. Iqbal M,
   3. Keller C,
   4. Criner G,
   5. Lee S,
   6. Fessler HE

   ; National Emphysema Treatment Trial (NETT) Research Group. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 2002;166(3):314-322.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   1. Hale K,
   2. Niewoehner D,
   3. Cosio MG

   . Morphologic changes in the muscular pulmonary arteries: relationship to cigarette smoking, airway disease, and emphysema. Am Rev Respir Dis 1980;122(2):273-278.

   OpenUrlPubMedWeb of Science
8. 8.↵
   1. Galiè N,
   2. Hoeper MM,
   3. Humbert M,
   4. Torbicki A,
   5. Vachiery JL,
   6. Barberà JA,
   7. et al

   ; Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34(6):1219-1263.

   OpenUrlFREE Full Text
9. 9.↵
   1. Hoeper MM,
   2. Andreas S,
   3. Bastian A,
   4. Claussen M,
   5. Ghofrani HA,
   6. Gorenflo M,
   7. et al

   . Pulmonary hypertension due to chronic lung disease: updated recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 2011;154(Suppl 1):S45-S53.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Chen SJ,
    2. Chen YF,
    3. Meng QC,
    4. Durand J,
    5. Dicarlo VS,
    6. Oparil S

    . Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995;79(6):2122-2131.

    OpenUrlAbstract/FREE Full Text
11. 11.
    1. Roig Figueroa V,
    2. Herrero Perzez A,
    3. Abad Lecha E,
    4. Ramos Cancelo I,
    5. Vielba Ramos D

    . Bosentan in pulmonary hypertension associated with hypoxaemic lung diseases. Curr Med Res Opin 2007;23(Suppl 2):S49-S53.

    OpenUrl
12. 12.↵
    1. Valerio G,
    2. Bracciale P,
    3. Grazia D'Agostino AG

    . Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Disease 2009;3(1):15-21.

    OpenUrl
13. 13.↵
    1. Stolz D,
    2. Rasch H,
    3. Linka A,
    4. Di Valentino M,
    5. Meyer A,
    6. Brutsche M,
    7. Tamm M

    . A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008;32(3):619-628.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Rabe KF,
    2. Hurd S,
    3. Anzueto A,
    4. Barnes PJ,
    5. Buist SA,
    6. Calverley P,
    7. et al

    ; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176(6):532-555.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. Abraham AS,
    2. Cole RB,
    3. Green ID,
    4. Hedworth-Whitty RB,
    5. Clarke SW,
    6. Bishop JM

    . Factors contributing to the reversible pulmonary hypertension of patients with acute respiratory failure studied by serial observations during recovery. Circ Res 1969;24(1):51-60.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Blanco I,
    2. Gimeno E,
    3. Muñoz PA,
    4. Pizarro S,
    5. Gistau C,
    6. Rodriguez-Roisin R,
    7. et al

    . Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2010;181(3):270-278.

    OpenUrlCrossRefPubMedWeb of Science